Drug interactions at the moment are the greatest impediment in managing HIV/HCV co-contaminated individuals. Regarding protection outcomes, tenofovir DF applied with ledipasvir or velpatasvir can lead to a rise in serum creatinine, especially when combined with a pharmacokinetic booster. [139] The u